eprintid: 824
rev_number: 8
eprint_status: archive
userid: 5
dir: disk0/00/00/08/24
datestamp: 2023-10-17 16:11:58
lastmod: 2023-10-17 16:11:58
status_changed: 2023-10-17 16:11:58
type: article
metadata_visibility: show
creators_name: Prayugo, A.D.
creators_name: Subroto, T.
creators_name: Arnafia, W.
title: Efficacy of Hemagglutinin Gene of Highly Pathogenic Avian Influenza as a Vaccine Candidate in Poultry: A Review
ispublished: pub
subjects: SF
divisions: j13
full_text_status: public
keywords: avian influenza vaccine; hemagglutinin; virus vector, antibody titer; Article; avian influenza virus; cross protection; drug design; drug efficacy; HA gene; highly pathogenic avian influenza; nonhuman; poultry; serology; survival rate; virus isolation; virus shedding
note: Master of Biotechnology Program, Graduate School, Universitas Padjadjaran, Jl. Dipati Ukur 35,West Java, Bandung, 40132, Indonesia; Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km 21,Jatinangor,West Java, Sumedang, 45363, Indonesia; Research and Development Division, PT Tekad Mandiri Citra, Jl. Mekar Raya Kav. 9,West Java, Bandung, 40292, Indonesia
abstract: The most prevalent fatal disease in poultry that can result in high morbidity and mortality is highly pathogenic avian influenza (HPAI), subtype H5N1. A vaccination program is the most frequent way to prevent HPAI cases in poultry, especially against the H5 subtype of HPAI. There are currently a number of avian influenza vaccines available, including recombinant and inactivated whole virus vaccines. The foundation of a recombinant vaccine is possible by the expression of an avian influenza gene of interest following insertion into a carrier vector (no pathogenic virus). A recombinant HPAI vaccine is required to further challenge avian influenza cases in poultry. As a recombinant vaccine inserted into a carrier vector, the hemagglutinin (HA) gene has proven effective. The recombinant Herpes Virus Turkey (rHVT) vector vaccine for avian influenza has been discovered and is commercially available. The rHVT vaccine was developed using a hemagglutinin insert from the HPAI virus clade 2.2. Overall, studies in this review aimed to determine the efficacy of any developed recombinant avian influenza vaccine that uses the HA gene from different clades challenged with any avian influenza virus (AIV) isolate. It was found that the efficacy of hemagglutinin as a recombinant vaccine could be promising for future HPAI vaccine development. In addition, it is possible to design a recombinant vaccine using local isolates to protect poultry farms, particularly in endemic regions © 2023, World's Veterinary Journal.All Rights Reserved.
date: 2023-03-25
publication: World's Veterinary Journal
volume: 13
number: 1
publisher: Scienceline Publication, Ltd
pagerange: 26-31
id_number: 10.54203/scil.2023.wvj3
refereed: TRUE
issn: 2322-4568
official_url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151832115&doi=10.54203%2fscil.2023.wvj3&partnerID=40&md5=2f0d673f6307febb636e79e6d0420b7e
j_index: scopus
citation:    (2023)     Efficacy of Hemagglutinin Gene of Highly Pathogenic Avian Influenza as a Vaccine Candidate in Poultry: A Review.   World's Veterinary Journal.  pp. 26-31.  ISSN 2322-4568   
document_url: http://eprints.science-line.com/id/eprint/824/1/WVJ%2013%281%29%2C%2026-31%2C%20March%2025%2C%202023.pdf